Intellectual Property India Publishes Patent Application for 'Nlrp3 Inflammasome Inhibitor And Use Thereof' Filed by Transthera Sciences (NANJING) Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517051414 A) filed by Transthera Sciences (NANJING) Inc., Jiangsu, China, on May 28, for 'nlrp3 inflammasome inhibitor and use thereof.'

Inventor(s) include Li, Lin; and Wu, Frank.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable salt, stereoisomer and deuterated product thereof, the definition of each group being as defined in the description. Studies have shown that the compound represented by general formula (A') or the pharmaceutically acceptable salt, stereoisomer and deuterated product thereof have high biological activity against an NLRP3 inflammasome, and have important clinical development value for the treatment of NLRP3-related diseases. Y-W-R3 (A')."

The patent application was internationally filed on Nov. 03, 2023, under International application No.PCT/CN2023/129677.

Disclaimer: Curated by HT Syndication.